HISUN(SH:600267) Shang Hai Zheng Quan Bao·2025-12-23 20:10Group 1 - Company has received approval for a supplemental application for Everolimus tablets, adding a new 2.5mg specification to the existing 5mg specification [1][2] - The approved drug, Everolimus, is indicated for various conditions including advanced renal cell carcinoma and neuroendocrine tumors [2][3] - The company has invested approximately 740,420 RMB in the development of the 2.5mg specification of Everolimus [3] Group 2 - The company’s subsidiary has received approval for veterinary products, including Doxycycline tablets and a vaccine for swine fever, enhancing its product line in the veterinary sector [6][8] - Doxycycline is indicated for infections caused by various bacteria, while the swine fever vaccine has an immunity period of six months [7][8] - The approval of these veterinary products is expected to strengthen the company's market position in the veterinary medicine sector [10]